TriVascular Technologies, Inc. 4
4 · TriVascular Technologies, Inc. · Filed Feb 4, 2016
Insider Transaction Report
Form 4
Thomas Robert
Director
Transactions
- Exercise/Conversion
Common Stock
2016-02-03$2.43/sh+16,523$40,151→ 106,639 total - Tax Payment
Common Stock
2016-02-03$5.62/sh−7,145$40,155→ 99,494 total - Disposition to Issuer
Common Stock
2016-02-03−9,378→ 90,116 total - Disposition to Issuer
Common Stock
2016-02-03−90,116→ 0 total - Exercise/Conversion
Stock Options (Right to buy)
2016-02-03−16,523→ 0 totalExercise: $2.43Exp: 2022-08-29→ Common Stock (16,523 underlying)
Footnotes (3)
- [F1]These shares were withheld by the issuer as payment of the exercise price and calculated for the purposes of the deemed exercise of the options, contingent upon closing of the Merger (as defined below), utilizing the closing price of the issuers common stock on January 28, 2016.
- [F2]These shares were disposed of pursuant to the merger agreement between the issuer and Endologix, Inc. (such transaction, the Merger). In connection with the closing of the Merger, the reporting person received 0.6312 share of Endologix common stock and $0.34 in cash for each share of issuer common stock held by such reporting person, for a total consideration of $4.95 per share based upon the closing price of Endologix common stock on February 2, 2016.
- [F3]These stock options became 100% vested in connection with the Merger.